pentoxifylline has been researched along with Alveolitis, Fibrosing in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tranilast has been used in allergic diseases because of its inhibitory effect on mast cells; it also has an anti-fibrotic effect in several diseases." | 5.35 | Effects of tranilast and pentoxifylline in a mouse model of chronic asthma using house dust mite antigen. ( Ahn, JH; Kim, CH; Kim, JS; Kim, JW; Kim, SC; Kim, SJ; Kim, YH; Kim, YK; Kwon, SS; Lee, JM; Lee, SH; Lee, SY; Yoon, HK, 2009) |
| "Previous discovery that long-term administration of pentoxifylline (PTX) to mice chronically exposed to smoke led to the development of pulmonary fibrosis rather than emphysema initiated our curiosity on whether the Wnt/β-catenin pathway, a set of signaling proteins essential to organ development and lung morphogenesis in particular were activated in the pathogenesis of pulmonary fibrosis." | 3.76 | Effects of pentoxifylline on Wnt/β-catenin signaling in mice chronically exposed to cigarette smoke. ( Chen, XL; Hu, XF; Peng, MJ; Wang, XR; Wang, Z; Zhang, JN; Zhao, TT; Zou, P, 2010) |
| "Radiation pneumonitis is usually a diagnosis of exclusion." | 2.52 | Radiation induced lung injury: prediction, assessment and management. ( Giridhar, P; Julka, PK; Mallick, S; Rath, GK, 2015) |
| "The pulmonary fibrosis has no known efficient treatment." | 1.40 | The relation of radiation-induced pulmonary fibrosis with stress and the efficiency of antioxidant treatment: an experimental study. ( Bozkurt, KK; Demırpence, Ö; Doğuç, DK; Kaya, V; Şen, CA; Süren, D; Yalçın, AY; Yazkan, R; Yıldırım, M; Yüksel, Ö, 2014) |
| "Tranilast has been used in allergic diseases because of its inhibitory effect on mast cells; it also has an anti-fibrotic effect in several diseases." | 1.35 | Effects of tranilast and pentoxifylline in a mouse model of chronic asthma using house dust mite antigen. ( Ahn, JH; Kim, CH; Kim, JS; Kim, JW; Kim, SC; Kim, SJ; Kim, YH; Kim, YK; Kwon, SS; Lee, JM; Lee, SH; Lee, SY; Yoon, HK, 2009) |
| "Therapy of idiopathic pulmonary fibrosis (IPF) is directed at 1) inhibition of alveolitis and tissue damage, and 2) inhibition of matrix deposition." | 1.30 | [Pentoxifylline inhibits experimental bleomycin-induced fibrosing alveolitis]. ( Entzian, P; Gerdes, J; Gerlach, C; Schlaak, M; Zabel, P, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Finato, AC | 1 |
| Almeida, DF | 1 |
| Dos Santos, AR | 1 |
| Nascimento, DC | 1 |
| Cavalcante, RS | 1 |
| Mendes, RP | 1 |
| Soares, CT | 1 |
| Paniago, AMM | 1 |
| Venturini, J | 1 |
| Kaya, V | 1 |
| Yazkan, R | 1 |
| Yıldırım, M | 1 |
| Doğuç, DK | 1 |
| Süren, D | 1 |
| Bozkurt, KK | 1 |
| Yüksel, Ö | 1 |
| Demırpence, Ö | 1 |
| Şen, CA | 1 |
| Yalçın, AY | 1 |
| Giridhar, P | 1 |
| Mallick, S | 1 |
| Rath, GK | 1 |
| Julka, PK | 1 |
| Kim, SJ | 1 |
| Kim, JW | 1 |
| Kim, YH | 1 |
| Lee, SH | 1 |
| Yoon, HK | 1 |
| Kim, CH | 1 |
| Ahn, JH | 1 |
| Lee, JM | 1 |
| Kim, JS | 1 |
| Kim, SC | 1 |
| Lee, SY | 1 |
| Kwon, SS | 1 |
| Kim, YK | 1 |
| Naranjo, TW | 1 |
| Lopera, DE | 1 |
| Diaz-Granados, LR | 1 |
| Duque, JJ | 1 |
| Restrepo, AM | 1 |
| Cano, LE | 1 |
| Wang, Z | 1 |
| Zhang, JN | 1 |
| Hu, XF | 1 |
| Chen, XL | 1 |
| Wang, XR | 1 |
| Zhao, TT | 1 |
| Peng, MJ | 1 |
| Zou, P | 1 |
| Entzian, P | 2 |
| Gerlach, C | 2 |
| Gerdes, J | 1 |
| Schlaak, M | 2 |
| Zabel, P | 2 |
| Zähringer, U | 1 |
| Galle, J | 1 |
| Delanian, S | 1 |
| Balla-Mekias, S | 1 |
| Lefaix, JL | 1 |
| Kremer, S | 1 |
| Breuer, R | 1 |
| Lossos, IS | 1 |
| Berkman, N | 1 |
| Christensen, TG | 1 |
| Connor, MW | 1 |
| Goldstein, RH | 1 |
| Or, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Controlled Phase Ⅱ Study of Preventively Use of Methylprednisolone After Split-course Chemoradiotherapy to Reduce the Risk of Radiation-induced Pulmonary Injury For Bulky Local Advanced None-small Cell Lung Cancer[NCT03661567] | Phase 2 | 52 participants (Actual) | Interventional | 2018-08-09 | Terminated (stopped due to slow enrollment) | ||
| Development of Radiation Fibrosis in Patients Treated With Pentoxyphylline and Vitamin E: a Prospective Randomized Study[NCT00583700] | Phase 2 | 54 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.[NCT00893035] | 885 participants (Actual) | Observational | 2006-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A primary outcome of interest is the composite Subjective, Objective, Management, and Analytic (SOMA) score at 18-month follow-up visit. Maximum score is 45, with a score of 0 being ideal and representing no treatment-related side effects at the study visit. (NCT00583700)
Timeframe: 18 month post-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Control Arm | 1.59 |
| Intervention: Pentoxifylline & Vitamin E | 1.0 |
"Tissue compliance meter measurements of the treated breast compared to the non-treated breast were obtained at 18 months post-radiation therapy. Tissue compliance simply means how soft and pliable the breast tissue is when force is applied to it.~One physician would hold the tissue compliance meter (TCM) against the participant's skin. A standard amount of force would be applied. A second physician would read the displacement scale for a specific set of areas on the breast. The range of the scale was 0 to 60 milimeters (mm). The physician's were blineded to the participant's intervention at the time of measurement.~The final value is the difference between the untreated and the treated breast [untreated - treated]. The range of these differences was -3.3 to 7.0 mm." (NCT00583700)
Timeframe: 18 months post-treatment
| Intervention | milimeters (mm) (Mean) |
|---|---|
| Control Arm | 2.10 |
| Intervention: Pentoxifylline & Vitamin E | 0.88 |
1 review available for pentoxifylline and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Radiation induced lung injury: prediction, assessment and management.
Topics: Aged; Alveolar Epithelial Cells; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; | 2015 |
9 other studies available for pentoxifylline and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis.
Topics: Animals; Antifungal Agents; Azithromycin; Cytokines; Disease Models, Animal; Drug Therapy, Combinati | 2020 |
The relation of radiation-induced pulmonary fibrosis with stress and the efficiency of antioxidant treatment: an experimental study.
Topics: Animals; Antioxidants; Ascorbic Acid; Histological Techniques; Pentoxifylline; Pulmonary Fibrosis; R | 2014 |
Effects of tranilast and pentoxifylline in a mouse model of chronic asthma using house dust mite antigen.
Topics: Animals; Anti-Allergic Agents; Antigens, Dermatophagoides; Asthma; Bronchial Hyperreactivity; Bronch | 2009 |
Combined itraconazole-pentoxifylline treatment promptly reduces lung fibrosis induced by chronic pulmonary paracoccidioidomycosis in mice.
Topics: Animals; Antifungal Agents; Collagen; Cytokines; Drug Therapy, Combination; Immunologic Factors; Itr | 2011 |
Effects of pentoxifylline on Wnt/β-catenin signaling in mice chronically exposed to cigarette smoke.
Topics: Animals; beta Catenin; Blotting, Western; Female; Immunohistochemistry; Mice; Mice, Inbred BALB C; P | 2010 |
[Pentoxifylline inhibits experimental bleomycin-induced fibrosing alveolitis].
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Male; Pentoxifylline; Phosphodiesterase Inhibitors; | 1997 |
Comparative study on effects of pentoxifylline, prednisolone and colchicine in experimental alveolitis.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Body Weight; Bronchoalveolar Lavage Fluid | 1998 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol.
Topics: Adult; Aged; Breast Neoplasms; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; M | 1999 |
Effect of immunomodulators on bleomycin-induced lung injury.
Topics: Adjuvants, Immunologic; Animals; Antibiotics, Antineoplastic; Bleomycin; Hydroxyquinolines; Male; Mi | 1999 |